Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P20366 (substance P)
 21,176 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antinociceptive effect of intracerebroventricularly (i.c.v.) administered [D-Arg1, D-Trp7,9, Leu11]-substance P (spantide), a non-selective tachykinin antagonist, was examined using the mouse formalin test. Licking behaviour induced by 2% formalin solution in the hindpaw of mice had two peaks, 0-5 min (first phase) and 10-30 min (second phase). I.c.v. spantide produced a dose-dependent antinociception during the first and second phases. The ID50 values were 2.95 (1.59-5.46) nmol for the first phase and 2.87 (1.49-5.52) nmol for the second phase. The antinociceptive effect in the first phase, but not in the second phase produced by spantide was antagonized by pretreatment with naloxone (1.0 mg/kg, i.p.), an opioid receptor antagonist. An opioid binding study using [3H]naloxone revealed that spantide was able to inhibit [3H]naloxone binding to mouse brain membrane preparations. These results suggest that opioid receptor systems in the mouse brain are involved in spantide-induced antinociception during the first phase, but not during the second phase of the formalin-induced nociceptive behaviour.
 ...
PMID:Involvement of opioid receptors in the antinociception produced by intracerebroventricularly administered spantide in mice. 858 65

Very limited structural information is available concerning the superfamily of G-protein-coupled receptors with their seven-transmembrane segments. Recently a non-peptide antagonist site was structurally and functionally replaced by a metal ion site in the tachykinin NK-1 receptor. Here, this Zn(II) site is transferred to the kappa-opioid receptor by substituting two residues at the outer portion of transmembrane V (TM-V), Asp223 and Lys227, and one residue at the top of TM-VI, Ala298, with histidyl residues. The histidyl residues had no direct effect on the binding of either the non-peptide antagonist [3H]diprenorphine or the non-peptide agonist, [3H]CI977, just as these mutations/substitutions did not affect the apparent affinity of a series of other peptide and non-peptide ligands when tested in competition binding experiments. However, zinc ions in a dose-dependent manner prevented binding of both agonist and antagonist ligands with an apparent affinity for the metal ion, which gradually was built up to 10(-6) M. This represents an increase in affinity for the metal ion of about 1000-fold as compared with the wild-type kappa receptor and is specific for Zn(II) as the affinity for e.g. Cu(II) was almost unaffected. The direct transfer of this high affinity metal ion switch between two only distantly related receptors indicates a common overall arrangement of the seven-helix bundle among receptors of the rhodopsin family.
 ...
PMID:Construction of a high affinity zinc switch in the kappa-opioid receptor. 862 61

In the decerebrated and spinalized rabbit, reflexes evoked in the gastrocnemius medialis muscle nerve by electrical stimulation of teh sural nerve are suppressed after blockade of NK-tachykinin receptors. This observation suggests that endogenous tachykinins tonically enhance transmission between sural nerve afferents and gastrocnemius motoneurons. In the present study we have investigated some possible sources of this tachykininergic tone. Electrical stimulation of the sural nerve at 1 Hz, as used in our previous investigation, leads to increased gastrocnemius reflex responses with successive stimuli. We examined reflexes evoked by pairs of sural stimuli separated by intervals of 10-1000 ms, and found that responses to the second stimuli of such pairs were significantly enhanced at intervals from 50 to 500 ms. Treatment with the NK receptor antagonist CP-99,994 [(+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine; 1 mg/kg, i.v.] reduced gastrocnemius reflex responses per se, but did not alter the facilitatory effects of pairing sural stimuli. Subsequent treatment with the glutamate N-methyl-D-aspartate receptor blocker dizocilpine (0.5 mg/kg, i.v.) further reduced reflex responses and abolished paired-pulse facilitation. In a second set of experiments, rabbits were prepared so that reflexes could be studied with minimal surgical preparation of the hindlimb. Reflex responses recorded in this way were enhanced by treatment with CP-99,994 (up to 1 mg/kg, i.v.). Subsequent administration of the opioid receptor antagonist naloxone (1-10 microg/kg, i.v.) increased reflexes, as seen previously in surgically-prepared animals. These data show that tachkininergic modulation of spinal reflexes in the rabbit results from the nociceptive input arising from surgical preparation of the leg. In contrast, tonic opioidergic inhibition of reflexes is not substantially dependent on such input.
 ...
PMID:Tachykininergic tone in the spinal cord of the rabbit: dependence on nociceptive input arising from invasive surgery. 863 22

Substance P (SP), a member of the tachykinin peptide family, has been found in high concentrations in the superficial laminae of the dorsal horn and it is thought to play a major role in the transmission of nociceptive information. Dynorphin(1-8), an opioid peptide with high selectivity for the kappa-opioid receptor subtype, is also found in the dorsal horn of the spinal cord. The aim of this study was to determine the effect of dynorphin(1-8) on the release of SP-like-immunoreactivity (SPLI) in the dorsal horn before and during the activation of peripheral nociceptors by a thermal stimulus. A push-pull canula was used to perfuse the dorsal horn of non-anesthetized decerebrate/spinal transected rats and the collected perfusates were assayed for SPLI by using radioimmunoassay. Dynorphin(1-8) applied to the spinal cord at a concentration of 1 microM elicited a 27 +/- 8% decrease in the basal release of SPLI and prevented the increase in the release of SPLI evoked by the application of a noxious thermal stimulus to the ipsilateral hind paw and lower limb. The effect of dynorphin(1-8) was reversed by 2 microM of nor-binaltorphimine (nor-BNI), a selective kappa opioid receptor antagonist. Application of nor-BNI alone to the perfusate resulted in a 62 +/- 23% increase in the basal release of SPLI. In conclusion, dynorphin(1-8) reduces the basal release of SPLI and prevents the increase in the release of SPLI elicited by the application of a noxious cutaneous thermal stimulus. This effect is mediated through the kappa-opioid receptor, which appears to tonically regulate the release of SPLI in the dorsal horn.
 ...
PMID:Kappa-opioid receptor modulation of the release of substance P in the dorsal horn. 872 Apr 94

It was found in the present study that low frequency (2Hz) electroacupuncture (EA) stimulation caused a decrease of the content of substance P immunoreactivity (SP-ir), whereas medium-(15Hz), high-(100Hz) and dense-disperse (D-D)- (2/15Hz) frequencies EA stimulation induced an increase of the content of SP-ir in the rat spinal fluid. EA analgesia induced by medium-, high- or D-D mode frequency was suppressed by nonpeptide SP (NK1) receptor antagonists CP96345 or RP67580 administered intrathecally (i.t.). Both the attenuation of SP release by low frequency EA and the potentiation of SP release by medium frequency EA in the spinal cord were blocked by the opioid receptor antagonist naloxone (i.t.). These results suggest that a decrease of release of SP-ir by low frequency and an increase of it by medium-, high- and D-D mode frequencies in the spinal cord facilitate analgesia.
 ...
PMID:[Study on a role of substance P in the spinal mechanisms of electroacupuncture analgesia]. 874 59

The effects of substance P (SP) and the naturally occurring met-enkephalin and the synthetic mu-specific opioid agonist, DAGO (Tyr-D-Ala-Gly-N-Methy-Phe-Gly-ol) and the delta-specific opioid agonist DADL (Tyr-D-Ala-Gly-Phe-D-Leu) on basal ventilation were investigated in halothane-anaesthetized rats. Local injections of SP (0.75-1.5 nmol) in the ventrolateral medulla oblongata (VLM), e.g. nucleus paragigantocellularis, and nucleus reticularis lateralis increased ventilation because of an elevation of tidal volume. Met-enkephalin induced a short-lasting ventilatory depression mainly because of a depression of tidal volume. Activation of delta- and mu-opioid receptors in the VLM by local application of DADL and DAGO, respectively, induced ventilatory depression, which was later in onset and more long-lasting. Local administration of met-enkephalin into the VLM also produced a long-lasting inhibition of the SP-induced ventilatory excitation. A similar blockade of the SP-induced excitatory ventilatory response could be elicited by DADL but not by DAGO. This antagonistic effect was attenuated by local application of the delta-opioid receptor antagonist ICI 154. 129. We conclude that the naturally occurring met-enkephalin as well as synthetic mu- and delta-specific enkephalin analogues (DAGO and DADL, respectively) in VLM depress basal ventilation by an effect on inspiratory drive. There is a functional antagonism between activation of delta-opioid receptors and SP receptors into the VLM in respect to respiratory regulation.
 ...
PMID:Substance P-induced respiratory excitation is blunted by delta-receptor specific opioids in the rat medulla oblongata. 880 Mar 56

Substance P (SP) has previously been shown to be involved in the transmission of nociceptive information in the spinal dorsal horn. In this study we investigated whether a functional interaction exists between SP and excitatory amino acids in the spinal cord of mice. Behavioral responses were observed after intrathecal co-administration of SP and N-methyl-D-aspartate (NMDA). The high dose (12 pmol) of SP potentiated NMDA (0.25 nmol)-induced behavior consisted of caudally directed licking and biting, while the low dose (1 pmol) of SP significantly reduced this behavior. This inhibitory effect of low dose of SP was blocked by intrathecal co-administration of opioid receptor antagonist naloxone (4 nmol). These results suggest that SP is also involved in the antinociception which is dependent on opioid mechanisms at the spinal level.
 ...
PMID:Spinal antinociceptive effect of substance P on the responses induced by intrathecally injected NMDA in mice. 881 68

1. The antinociceptive action of clonidine (Clon) and the interactions with alpha 1, alpha 2 adrenoceptor and opioid receptor antagonists was evaluated in mice by use of chemical algesiometric test (acetic acid writhing test). 2. Clon produced a dose-dependent antinociceptive action and the ED50 for intracerebroventricular (i.c.v.) was lower than for intraperitoneal (i.p.) administration (1 ng kg-1 vs 300 ng kg-1). The parallelism of the dose-response curves indicates activation of a common receptor subtype. 3. Systemic administration of prazosin and terazosin displayed antinociceptive activity. Pretreatment with prazosin produced a dual action: i.c.v. Clon effect did not change, and i.p. Clon effect was enhanced. Yohimbine i.c.v. or i.p. did not induce antinonciception, but antagonized Clon-induced activity. These results suggest that alpha 1- and alpha 2-adrenoceptors, either located at the pre- and/or post-synaptic level, are involved in the control of spinal antinociception. 4. Naloxone (NX) and naltrexone (NTX) induced antinociceptive effects at low doses (microgram kg-1 range) and a lower antinociceptive effect at higher doses (mg kg-1 range). Low doses of NX or NTX antagonized Clon antinociception, possibly in relation to a preferential mu opioid receptor antagonism. In contrast, high doses of NX or NTX increased the antinociceptive activity of Clon, which could be due to an enhanced inhibition of the release of substance P. 5. The results obtained in the present work suggest the involvement of alpha 1-, alpha 2-adrenoceptor and opioid receptors in the modulation of the antinociceptive activity of clonidine, which seems to be exerted either at spinal and/or supraspinal level.
 ...
PMID:alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception. 889 77

The present study was undertaken to investigate the effects of the opioid peptide Met-enkephalin (met-enk) on the release of substance P-like immunoreactivity (SPLI) in the lumbar dorsal horn during the application of a noxious mechanical or thermal stimulus to the ipsilateral hind paw and lower limb of the rat. A push-pull cannula was introduced to the lumbar dorsal horn in non-anesthetized decerebrate/spinal transected rats. The dorsal horn was perfused with artificial CSF and the collected perfusates were assayed for SPLI using radioimmunoassay. A noxious mechanical or thermal stimulus was applied to different areas of the ipsilateral hind paw and lower limb. Met-enk (500 nM) applied to the dorsal horn through the perfusate reduced the basal release of SPLI by 29 +/- 9% and prevented the increase in the release of SPLI evoked by the noxious mechanical or thermal stimulus. The effect of met-enk was blocked by the selective delta-opioid receptor antagonist naltrindole (500 nM). Naltrindole (NTD) alone elicited a 75 +/- 30% increase in the basal release of SPLI. These data show that met-enk inhibits the thermally or mechanically evoked release of SPLI in the dorsal horn by activating the delta opioid receptors. These receptors are also involved in the tonic spinal regulation of the release of SPLI.
 ...
PMID:Delta-Opioid receptor modulation of the release of substance P-like immunoreactivity in the dorsal horn of the rat following mechanical or thermal noxious stimulation. 893 Mar 37

An orphan receptor resembling the neurokinin 3 tachykinin receptor (NK3), initially claimed to be an atypical opioid receptor, is shown herein to respond potently to the physiological NK3 receptor ligand, neurokinin B. This 'NK4' receptor did not give functional responses in Xenopus oocytes to opioid agonists. However, NK4 receptor activation was inhibited by nanomolar concentrations of dynorphin. The NK4 receptor is therefore a tachykinin receptor which is functionally antagonized by an endogenous opioid peptide.
 ...
PMID:Functional characterization by heterologous expression of a novel cloned tachykinin peptide receptor. 894 59


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>